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Combining currently available antibiotics to optimize their use is a promising strategy
to reduce treatment failures against biofilm-associated infections. Nevertheless, most
assays of such combinations have been performed in vitro on planktonic bacteria
exposed to constant concentrations of antibiotics over only 24 h and the synergistic
effects obtained under these conditions do not necessarily predict the behavior of
chronic clinical infections associated with biofilms. To improve the predictivity of in vitro
combination assays for bacterial biofilms, we first adapted a previously described
Hollow-fiber (HF) infection model by allowing a Staphylococcus aureus biofilm to form
before drug exposure. We then mimicked different concentration profiles of amikacin
and vancomycin, similar to the free plasma concentration profiles that would be
observed in patients treated daily over 5 days. We assessed the ability of the two
drugs, alone or in combination, to reduce planktonic and biofilm-embedded bacterial
populations, and to prevent the selection of resistance within these populations.
Although neither amikacin nor vancomycin exhibited any bactericidal activity on
S. aureus in monotherapy, the combination had a synergistic effect and significantly
reduced the planktonic bacterial population by −3.0 to −6.0 log10 CFU/mL. In parallel,
no obvious advantage of the combination, as compared to amikacin alone, was
demonstrated on biofilm-embedded bacteria for which the addition of vancomycin
to amikacin only conferred a further maximum reduction of 0.3 log10 CFU/mL. No
resistance to vancomycin was ever found whereas a few bacteria less-susceptible to
amikacin were systematically detected before treatment. These resistant bacteria, which
were rapidly amplified by exposure to amikacin alone, could be maintained at a low level
in the biofilm population and even suppressed in the planktonic population by adding
vancomycin. In conclusion, by adapting the HF model, we were able to demonstrate
the different bactericidal activities of the vancomycin and amikacin combination
on planktonic and biofilm-embedded bacterial populations, suggesting that, for
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biofilm-associated infections, the efficacy of this combination would not be much greater
than with amikacin monotherapy. However, adding vancomycin could reduce possible
resistance to amikacin and provide a relevant strategy to prevent the selection of
antibiotic-resistant bacteria during treatments.
Keywords: hollow-fiber infection model, antibiotic combination, amikacin, vancomycin, biofilm, antimicrobial
resistance, Staphylococcus aureus
INTRODUCTION
Staphylococcus aureus possesses the ability to form biofilms and
is responsible for chronic infections which are hard to treat and
cause significant morbidity and mortality.
Biofilms are communities of bacteria which adhere to
surfaces and are encapsulated in a self-produced extracellular
polysaccharide matrix. They constitute an important strategy
implemented by microorganisms to survive in harsh
environmental conditions (Donlan and Costerton, 2002).
Biofilms are responsible for chronic, recurrent infections and
are known to survive very high concentrations of antibiotics
(Lewis, 2008; Lebeaux et al., 2014). One hypothesis to explain
the lower activity of antimicrobial drugs on biofilms is the
high prevalence of persister cells in biofilms (Lewis, 2008;
Singh et al., 2009). These persisters, unlike resistant bacteria
which are genetically modified, consist of clones of bacteria
expressing a different but reversible phenotype which allows
them to transiently escape the effects of antibiotics (Lewis,
2008).
The antibiotic therapies currently used against biofilm
infections are often associated with poor clinical responses and
frequent relapses (Davies, 2003). For several years, different
solutions have been proposed to eradicate biofilm bacteria such as
phages, quorum sensing inhibitors or physical methods (Ivanova
et al., 2017). However, although highly innovative strategies still
need to be developed to deal with severe infections by both
tolerant and multi-resistant bacteria, the method which can most
rapidly and easily be implemented in patients at present is to
combine existing drugs or to modify their therapeutic regimen
(dose, frequency, and mode of administration).
In the case of suspected S. aureus infection, vancomycin
therapy is often initiated in patients to provide antibacterial
activity against both Methicillin-Sensitive S. aureus (MSSA)
and Methicillin-Resistant S. aureus (MRSA) (Deresinski, 2009).
However, although vancomycin can kill planktonic bacteria, its
activity against Biofilm-Embedded Bacteria (BEB) is quite low.
Lebeaux et al. (2015) showed that after exposure to a very high,
constant concentration of vancomycin (5000 mg/L) for 24 h,
the percentage of bacteria surviving in a 24 h-old S. aureus
biofilm exceeded 20% and was even close to 100% for 2 of the
4 tested strains. Singh et al. (2009) reported similar results and
found no statistically significant difference between the bacteria
remaining in a non-treated S. aureus biofilm or in a biofilm
exposed for 24 h to vancomycin concentrations equal to or higher
than those clinically achievable. Post et al. (2017) demonstrated
that vancomycin is able to eradicate a mature biofilm of
S. aureus from metal implants by using a static concentration
of 200 mg/L over 28 days. Nevertheless, such a concentration
profile cannot be achieved by systemic administration or local
delivery vehicles currently available. To overcome this poor
activity on biofilms, an aminoglycoside is often combined
with vancomycin. Synergistic activity between vancomycin and
aminoglycosides had already been demonstrated on S. aureus
(Watanakunakorn and Glotzbecker, 1974; Cokça et al., 1998) but
these studies were performed by exposing planktonic bacteria
for no more than 24 h to constant antibiotic concentrations
whereas in the in vivo situation, antibiotic concentrations
continuously fluctuate over several days. The effects of a
combination of gentamicin and vancomycin on S. aureus
were more rarely tested under dynamic in vitro conditions
with varying antibiotic concentrations or in animal models of
infection. No significant synergy was observed in two studies
where low inocula of S. aureus were exposed to the two drugs
(Backo et al., 1999; Aeschlimann et al., 2000). Another study on
large inocula of MRSA and MSSA, representative of a biofilm-
associated infection, was performed in an in vitro simulated
endocardial vegetation model. The effect of vancomycin alone
was statistically significant compared to the control after 3 days
but the activity of vancomycin on MSSA or MRSA was not
improved by adding gentamicin (LaPlante and Woodmansee,
2009). However, in this study, the vancomycin concentrations
tested were almost two times higher than the free and
active concentrations routinely obtained in patients because
no correction was performed for the 45% plasma protein
binding of vancomycin (Liu et al., 2002; Butterfield et al.,
2011).
To propose new treatment optimizations, the predictivity of
in vitro experiments needs to be improved, for example by
exposing both planktonic and BEB in parallel over the complete
duration of treatment (several days), to drug concentrations
identical to those that would be encountered under clinical
conditions in patients.
In this study, we studied the effects of amikacin, an
aminoglycoside, and vancomycin on planktonic and biofilm-
embedded S. aureus by using an in vitro dynamic model,
the Hollow-Fiber (HF) infection model, which mimics the
fluctuations of antibiotic concentrations over time, as would
occur in the plasma of patients during a 5-day treatment. The HF
model was recently labeled by the European Medicines Agency
(European Medicines Agency, 2015; Gumbo et al., 2015) for
drug dosage optimization in the treatment of tuberculosis. We
have further adapted this model to explore drug activity not
only on planktonic but also on biofilm-embedded S. aureus.
Indeed, in previous studies conducted in HF (Nicasio et al.,
2012; Ferro et al., 2015), the bacteria were systematically
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exposed to drugs during the exponential phase of growth,
when there was no time for biofilm development, whereas
in this study, the biofilm was allowed to form for 3 days
before drug exposure. The killing effects of drugs and the
potential selection of resistance were assessed both on planktonic
bacteria over time and on BEB at the end of exposure. We
first compared monotherapy and combinations of amikacin and
vancomycin at the currently recommended dosing regimens,
i.e., 1g vancomycin twice a day and 15 mg/kg amikacin once
a day for 5 days. Such therapeutic regimens are considered
sufficient to achieve the PK/PD indices classically expected to
obtain drug efficacy. For aminoglycosides, the most predictive
PK/PD index is the Maximal Concentration (Cmax) divided
by the Minimal Inhibitory Concentration (MIC) ratio (Moore
et al., 1987) and a value from 8 to 10 is usually recommended
to ensure efficacy against the pathogen (Toutain et al., 2002).
For vancomycin, the best predictive index is the AUC over
24 h divided by the MIC (AUC24h/MIC) (Nielsen et al.,
2011), and value of 400 is recommended to achieve clinical
effectiveness (Rybak et al., 2009; Jung et al., 2014; Song et al.,
2015).
We then explored the effects of a slight deviation from these
standard dosages by simulating an increased dose of amikacin,
which is a concentration-dependent antibiotic, (Frimodt-Møller,
2002) and by modifying the mode of administration (infusion
vs. bolus) of vancomycin, which is a time-dependent antibiotic
(Waineo et al., 2015).
MATERIALS AND METHODS
Bacterial Strain
The Methicillin-sensitive S. aureus strain HG 001, derived from
NCTC 8325, was used for all experiments.
Antimicrobial Agents
Amikacin sulfate powder (Amikacine Mylan R©) and vancomycin
chlorhydrate powder (Vancomycine Sandoz R©) were used to
prepare antibiotic stock solutions with water. Vials were stored
at −20◦C for less than 1 month and were thawed and diluted to
the desired concentrations for the assay just before each antibiotic
administration.
Minimal Inhibitory Concentration (MIC)
Determination
Minimal inhibitory concentrations of vancomycin and
amikacin on the MSSA strain were performed in triplicate
by broth microdilution in cation-adjusted Mueller Hinton
broth (Ca-MH, Mueller-Hinton II, Sigma Aldrich, Saint
Quentin-Fallavier, France) according to the CLSI reference
methods (Clinical and Laboratory Standards Institute [CLSI],
2012), and also in Roswell Park Medium Institute 1640
Medium (RPMI, Gibco, Thermo Fischer Scientific, MA,
United States). Briefly, a bacterial suspension, diluted in
Mueller-Hinton Broth or RPMI to give a final organism density
of 5.7 log10 CFU/mL, was added to wells of a microtiter
plate containing serial twofold dilutions of vancomycin or
amikacin. Growth was recorded after incubation for 18 h at
35◦C.
PK/PD Study
Hollow-Fiber Infection Model
A HF infection model was used to assess the antibacterial activity
of the combination of amikacin and vancomycin on planktonic
and biofilm-embedded S. aureus during exposure to fluctuating
clinically relevant antibiotic concentrations. A diagrammatic
representation of the Hollow Fiber Infection Model was kindly
provided by FiberCell Systems R© (Figure 1). Basically, the HF
model includes a cartridge with capillaries composed of a
semipermeable polysulfone membrane. The pore size of the
capillaries (42 kDa) allows equilibration of the concentrations
of chemicals which circulate through the central and peripheral
compartments by means of a peristaltic pump (Duet pump,
FiberCell Systems, Inc., Frederick, MD, United States) while the
bacteria stay confined to the extracapillary space in the peripheral
compartment.
In this study, twenty milliliters of a suspension containing
5.7 log10 CFU/mL of S. aureus were inoculated into the
extracapillary space of each hollow-fiber cartridge (C2011
polysulfone cartridge, FiberCell Systems, Inc., Frederick, MD,
United States) and incubated at 37◦C in RPMI from Day 0 (D0)
to Day 2 (D2) without any drug, to allow biofilm formation.
From D3 to D7, the bacteria were then subjected to amikacin
and/or vancomycin. The drugs were added to the central
compartment to obtain the maximum concentration (Cmax)
and were continuously diluted with RPMI by means of a
peristaltic pump (Mini Rythmic PN+, SMD, Fleury-sur-Orne,
France) to mimic the human terminal half-life of each antibiotic.
The antibiotics also constantly circulated through the central
and peripheral compartments by means of a second peristaltic
pump (Duet pump, FiberCell Systems, Inc., Frederick, MD,
United States).
The first antibiotic exposure tested in the HF model simulated
the plasma concentrations of patients receiving 15 mg/kg
amikacin once a day (Kato et al., 2017) and/or 1 g vancomycin
every 12 h (Nicasio et al., 2012). Since the free plasma drug
concentration is known to be one of the best surrogates of
the concentration at the site of infection (Liu et al., 2002),
we exposed the bacteria in the HF model to concentrations
similar to the free plasma concentrations obtained in patients
after administration of the above dosing regimens. For amikacin,
plasma protein binding was considered negligible and a plasma
Cmax of treated patients ranging from 60 to 80 mg/L (A70
treatment) was reproduced in the HF model (Gálvez et al.,
2011). For vancomycin, plasma protein binding is around 45%
(Butterfield et al., 2011) so the total plasma concentrations
obtained from patients described in the literature were corrected
to calculate the free Cmax of 18 µg/mL, which was then simulated
in the HF model (V18 treatment) (Mandell et al., 2007). The
simulated elimination half-life for both drugs in the HF model
(4 h) was similar to the plasma elimination half-lives of amikacin
and vancomycin in patients (Matzke et al., 1986; Adamis et al.,
2004).
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FIGURE 1 | Diagrammatic representation of the Hollow Fiber Infection Model kindly provided by FiberCell Systems R© (Cadwell, 2015). Bacteria were trapped by the
hollow fiber capillaries in the cartridge (see also embedded photo). Drugs were added to the central reservoir and freely circulated through the cartridge and bacteria
by means of the Fibercell Systems Duet pump R© (FiberCell Systems, Inc., Frederick, MD, United States). Drug concentrations decreased over time after drug
administrations, due to the continuous addition of a diluent (RPMI) by means of another set of pumps (here, Mini Rythmic R© PN+, SMD, Fleury-sur-Orne, France).
For the combinations, we first tested both drugs at the
current dosing regimens for amikacin and vancomycin (A70
V18 treatment) and then simulated different pharmacokinetic
profiles. We then tested two higher peak concentrations of
90 µg/mL (A90 V18 treatment) and 130 µg/mL (A130 V18
treatment) of amikacin, that could theoretically be attained
in patients with a dose of 2500 mg (Álvarez et al., 2016),
to investigate the relation between amikacin concentration
and activity. For vancomycin, a dosage of 2 g a day has
been recently recommended (Patel et al., 2011; Waineo et al.,
2015), so a Continuous Rate Infusion (CRI) of 2 g a
day of vancomycin was simulated by directly adding the
drug to the fresh diluting medium to obtain a constant
vancomycin concentration of 9 µg/mL (A70 CRIV9 treatment)
(Hanrahan et al., 2015). All the experiments, including control
and exposure to amikacin and vancomycin in monotherapy
or in combination, were performed in duplicate to check
reproducibility.
Planktonic Bacteria Quantification
One milliliter samples were collected from the extracapillary
space in the HF cartridge to count the planktonic bacteria at
0 h (baseline), 2, 4, 6, 8, and 10 h after the morning antibiotic
administration each day for 5 days (D3 to D7). The samples
were centrifuged at 3000 g for 10 min. The supernatant was
removed and the pellet resuspended in 1 mL of NaCl 0.9%. The
suspension was then serially diluted and the bacteria counted in
triplicate after an overnight incubation at 37◦C on tryptic soy agar
supplemented with magnesium sulfate and activated charcoal to
prevent any carry-over effect of the antibiotic. The counts were
verified again 8 h after to include colonies that could have slower
grown. The limit of detection was 2.5 log10 CFU/mL.
After two washes to remove the antibiotic contained in the
suspension, the less-susceptible planktonic bacteria were counted
once a day prior to morning antibiotic administrations from
D3 to D7 on agars containing threefold (3 µg/mL) and sixfold
MIC (6 µg/mL) of amikacin or vancomycin. The plates were
incubated for 3 days at 37◦C before the bacteria were counted.
The proportion of less-susceptible bacteria in the total bacterial
population was calculated as the ratio of the colony counts on
drug-supplemented agar divided by the colony counts on drug-
free agar at the same sampling time.
Biofilm Bacteria Quantification
At the end of the experiment (D7), the extracapillary space in
the cartridge containing the bacteria was washed four times
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with 50 mL of sterile NaCl 0.9% to remove the planktonic
bacteria. The biofilm was then disrupted by sonication of the
cartridge for 15 min at 42 kHz (Bransonic 5800, Branson
Ultrasonics Corporation, Emerson, Angouleˆme, France) which
suspended the BEB in the 20 ml of NaCl 0.9% remaining in
the cartridge after the washes. These bacteria were collected
for quantification with the same technic as for planktonic
bacteria. The colonies were plated on the drug-free and drug-
supplemented agar and were counted, before and after ultrasound
treatment. After an overnight incubation at 37◦C, or more
if needed, the size of the biofilm was calculated in log10
CFU/mL from the difference between the bacterial counts in
the extracapillary space before and after ultrasound treatment.
For each combination, the MIC of amikacin or vancomycin was
also determined on a single bacterial colony growing on the
drug-containing agar plates to accurately quantify the loss of
susceptibility.
Drug Assay
Samples for antibiotic quantification were withdrawn from
the central reservoir and from the extracapillary space of the
cartridge before and after each antibiotic administration and at
2, 4, 6, and 8 h on the 1st day and twice a day thereafter. Samples
were centrifuged at 3000 g for 10 min and stored at −20◦C for
less than 2 months before dosing.
Samples were prepared in 1.5 mL tubes. Two hundred µL
of 15% of trichloroacetic acid containing the vancomycin d12
and amikacin d5 internal standards at 10 µg/mL were added to
100 µL of calibrators, quality controls, or samples. Antibiotics
were quantified on an Acquity ultra performance liquid
chromatography (UPLC) coupled to a Xevo triple quadrupole
mass spectrometer (Waters, Milford, MA, United States).
Chromatographic data were monitored by Targetlynx software
(Waters, Milford, MA, United States). The method was validated
in terms of linearity, sensitivity and repeatability. Accuracies
ranged from 84 to 94% and from 99 to 107% with CV intra-
day precisions below 9 and 10% for amikacin and vancomycin,
respectively. The limit of quantification was set at 0.5 µg/mL for
both antibiotics.
The concentration of antibiotic in the system was calculated
according to equation 1.
Statistics
The planktonic bacterial inoculum sizes before (D3) and after
(D7) in the 5-day combined treatments were compared by
applying a paired T-test with the R R© software (R Development
Core Team, 2014).
The sizes of the planktonic bacteria and BEB populations after
treatment with the amikacin and vancomycin combination for
5 days (D7) were also compared by paired T-test with R R©.
RESULTS
Minimal Inhibitory Concentration (MIC)
The MIC of vancomycin, for the S. aureus strain tested,
was 1 µg/mL both in Ca-MH and in RPMI and the MIC
of amikacin was 1 µg/mL in Ca-MH and 0.5 µg/mL in
RPMI. Based on the EUCAST breakpoints, the tested strain
was therefore considered as susceptible to vancomycin and
amikacin.
PK Analysis
The concentrations in the central compartment and in the
extra capillary space of the cartridge (containing bacteria)
attained equilibrium within 15 min after adding the antibiotic
to the central compartment (data not shown). The predicted
vs. observed free concentration-time profiles of amikacin and
vancomycin in the HF model, corresponding to the dosing
regimen of 15 mg/kg of amikacin once a day (A70) and
1 g of vancomycin every 12 h (V18), are provided in
Figure 2.
For vancomycin, the targeted AUC24 h was 400 µg.h.mL−1,
i.e., 16.6 times the MIC over 24 h (Toutain et al., 2007), and
AUC24 h ranging from 372 to 417 µg.h.mL−1, i.e., deviations
ranging from −7.0 to +4.3% from the targeted AUC24 h, were
obtained. For amikacin, the targeted Cmax was 70 µg/mL and, at
steady-state, a Cmax of 59.3 ± 25.8 µg/mL (mean ± SD) i.e., a
mean deviation of 15.3% from the expected Cmax, was obtained.
FIGURE 2 | Expected (blue lines) and observed (red circles)
concentration-time profiles in the Hollow Fiber system from D3 to D7 for
(A) vancomycin after administrations twice a day with peak concentrations of
18 µg/mL (V18 treatment) and for (B) amikacin after administrations once a
day with peak concentrations of 70 µg/mL.
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FIGURE 3 | Mean ± SD of the bacterial counts (log10 CFU/mL) for planktonic
(in orange) and biofilm-embedded bacteria (in blue) at the end of the
experiments (D7) for control assays and the different treatments (n = 2 for
each antibiotic combination). The BEB population was smaller than the
planktonic population in the control experiments, and also after monotherapy
with amikacin or vancomycin. In contrast, the BEB populations were 1.2–2.0
log10 CFU/mL higher than the planktonic populations (p < 0.001).
PK/PD Study
Killing Activity on Planktonic Bacterial Populations
After incubation for 3 days in the HF cartridge (D3), the
planktonic and biofilm populations of S. aureus were 9.3 ± 0.3
log10 CFU/mL and 8.4± 0.1 log10 CFU/mL, respectively.
In the absence of antibiotic (control experiments), the
planktonic and biofilm populations remained quite stable for a
further 5 days with bacterial counts of 10.8 ± 0.2 log10 CFU/mL
and 8.1 ± 0.1 log10 CFU/mL, respectively, at the end of the
experiments (D7) (Figure 3).
The time-kill curves for the planktonic bacteria associated
with the 3-days old biofilm and exposed to amikacin or
vancomycin alone and the bacterial counts of planktonic bacteria
growing on agar supplemented with threefold MIC of amikacin
over time during A70 treatment for 5 days (from D3 to D7) are
shown in Figure 4. After 5 days of exposure to vancomycin (from
D3 to D7) administered twice a day with a peak concentration
of 18 µg/mL (V18 treatment), the planktonic population never
decreased below the initial population size. After exposure to
amikacin administered once a day with a peak concentration of
70 µg/mL (A70 treatment), a mean reduction of 0.9 log10 was
observed over the 1st day of treatment (D3) but after 5 days (D7),
the size of the planktonic population, 9.2 ± 0.7 log10 CFU/mL,
was very similar to that of the population before exposure to
amikacin and not much lower than in the control experiments.
We then assessed the killing activity of the amikacin and
vancomycin combinations over 5 days (from D3 to D7). For
amikacin, three peak concentrations of 70 (A70 V18 treatment),
95 (A95 V18 treatment), or 130 (A130 V18 treatment) µg/mL
were tested and for vancomycin, a single peak concentration
of 18 µg/mL (A70 V18 treatment) twice a day was compared
FIGURE 4 | Changes in the planktonic bacterial populations (log10 CFU/mL)
after exposure to amikacin or vancomycin in monotherapy from D3 to D7. Full
circles represent the bacterial counts in the HF model during 5 days of
treatment with vancomycin twice a day (V18 treatment, in blue) or amikacin
once a day (A70 treatment, in orange). Full red squares represent the bacterial
counts of planktonic bacteria growing on agar supplemented with threefold
MIC of amikacin over time during A70 treatment. Mean ± SD of the bacterial
counts are shown (n = 2 for each treatment).
FIGURE 5 | Changes in the planktonic bacterial population (log10 CFU/mL)
after exposure to combinations of amikacin and vancomycin from D3 to D7.
The marks represent the mean ± SD of the bacterial counts for the different
tested treatments [blue: A70 V18 treatment, red: A95 V18 treatment, green:
A130 V18 treatment and black: A70 CRIV9 treatment (n = 2 for each antibiotic
combination)]. The reduction of the planktonic bacterial population between
the 1st day (D3) and the last day (D7) of treatments with combinations of
amikacin and vancomycin was significant (p < 0.001).
to a steady concentration of 9 µg/mL (A70 CRIV9 treatment).
The time-kill curves of planktonic bacteria exposed to the drug
combinations from D3 to D7 are shown in Figure 5. Similar time-
kill profiles were observed for the planktonic bacteria, whatever
the drug concentration profiles tested. The mean decrease of
the bacterial population during the 1st day of treatment (D3)
with the different drug combination regimens was very similar
and ranged from −0.9 to −1.4 log10 CFU/mL, followed by
stabilization or a slight increase overnight. The killing activity
of the drugs during the following days (D4–D7) ranged from
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a decrease of 3.0 log10 to an increase of 0.5 log10 of the
planktonic population between two successive administrations of
amikacin.
After exposure to combinations for 5 days (D7), no
eradication of planktonic bacteria was observed but the overall
reduction ranged from −3.0 log10 to −6.0 log10 compared to
the population before drug exposure. This reduction of the
planktonic bacterial population between the 1st day (D3) and
the last day (D7) of treatments with combinations of amikacin
and vancomycin was significant (p < 0.001) whereas amikacin
or vancomycin alone failed to reduce the planktonic population
over 5 days (the planktonic bacterial populations were equal
to or higher after monotherapy than before monotherapy,
Figure 4).
Killing Activity on BEB
The counts of biofilm-embedded bacteria recovered at the end of
each experiment (D7) and the planktonic bacterial counts at the
same time point are compared in Figure 3.
After exposure to vancomycin alone, the BEB count was
9.2 ± 0.7 log10 CFU/mL, i.e., approximately one log10
higher than the biofilm without treatment, while amikacin
alone (A70) decreased the size of the biofilm by 0.6 log10
CFU/mL. The addition of vancomycin (V18 or CRI V9) to
amikacin (A70) did not increase BEB reduction and showed
that the combination did not exhibit any synergy on these
bacteria.
In parallel, we observed that the BEB population was smaller
than the planktonic population in the control experiments,
and also after monotherapy with amikacin or vancomycin. In
contrast, the BEB populations were 1.2 to 2.0 log10 CFU/mL
higher than the planktonic populations (p < 0.001) in all the
combination experiments.
FIGURE 6 | Mean ± SD of the bacterial counts (log10 CFU/mL) of total
planktonic bacteria (dark orange) and bacteria growing on agar supplemented
with three-times the MIC of amikacin (medium orange) and six-times the MIC
of amikacin (light orange) in the control experiment or after 5 days of exposure
to different treatments (D7) (n = 2 for each condition).
Prevention of the Selection of Resistance
No bacterial growth was observed on vancomycin-supplemented
agar, whatever the experiment.
The counts of planktonic bacteria and BEB growing on
agar supplemented with 3-MIC and 6-MIC-amikacin, after
exposure to the drugs for 5 days (D7), are compared to the
total counts in Figures 6, 7. Less-susceptible bacteria were
systematically observed on the amikacin- supplemented agar
plates before any drug exposure (D3) at a proportion of
about 10−6 of the total bacterial population for planktonic
bacteria (assessed in all the experiments) and BEB (assessed
in control experiments). Similar proportions (around 10−6)
were also found at the end of the control experiments
(D7).
After 5 days of exposure to amikacin alone (D7), all
the planktonic bacteria and BEB (proportion around 1)
were able to grow on 6MIC-amikacin agar (Figure 6),
which implied that the less-susceptible bacterial population,
rather than fully susceptible bacteria, was selected by the
drug. The time-development of the less-susceptible planktonic
population, represented in Figure 4, showed that the fully
susceptible population was drastically reduced from the 3rd
day of treatment (D5). The addition of vancomycin to
amikacin reduced the counts of planktonic bacteria growing
on 3-MIC-amikacin and 6-MIC-amikacin, which were only
detected in 4 on 1 out of 8 assays, respectively. Exposure of
biofilm to the drug combinations, rather than to amikacin
alone, also reduced the populations of less-susceptible bacteria
(Figure 7).
The highest MIC of amikacin for the sampled biofilm bacteria
was 16 µg/mL (a 16-fold increase), corresponding to bacteria
with intermediate amikacin-susceptibility with regard to the
EUCAST breakpoints.
FIGURE 7 | Mean ± SD of the bacterial counts (log10 CFU/mL) of total
biofilm-embedded bacteria (dark blue) and of biofilm-embedded bacteria
growing on agar supplemented with three-times the MIC of amikacin (blue)
and six-times the MIC of amikacin (light blue) in the control experiment or after
5 days of exposure to different treatments (D7) (n = 2 for each condition).
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DISCUSSION
Due to the refractoriness of S. aureus biofilm infections to
antibiotic treatments, there is an urgent need to optimize the
use of currently available drugs to ensure bacterial killing
and the prevention of resistance. In this study, we developed
an innovative use of the HF model by delaying exposure to
the antibiotics and studied the effects of a combination of
vancomycin and amikacin both on planktonic bacteria and on
BEB in conditions representative of clinical situations. Different
concentration profiles of the drugs were tested, and bacteria
were subjected to the fluctuating concentrations that might be
encountered in patients during a complete treatment. These
experimental conditions should have greater predictive value
than simple static assays in which bacteria are exposed to
a fixed concentration over time. Moreover, due to the lack
of medium renewal in static assays, such experiments are
often conducted over 24 h whereas longer periods are needed
to assess the selection of resistance by antibiotics (Drusano,
2017). Compared to animal models, which may exhibit very
different pharmacokinetics to humans and in which some human
pathogens cannot develop, all bacteria can be cultured in the HF
model and exposed to drug concentration profiles that mimic the
range of human profiles (Toutain et al., 2010). For example, as
vancomycin is eliminated much faster in mice (half-life = 32 min)
than in humans (Knudsen et al., 2000), dosage regimens tested in
mice can hardly be extrapolated to humans. Obviously, the main
weakness of static or dynamic in vitro assays is the absence of the
immune system which can cooperate with antibiotics to clear an
infection.
Several in vitro studies in dynamic systems including the
HF model (Nicasio et al., 2012; Lenhard et al., 2016) have
investigated the antibacterial activity of drugs combined with
vancomycin against planktonic S. aureus. However, the use of
dynamic in vitro systems, such as the CDC biofilm device or
others, to study the effects of combinations on biofilm is rarely
reported. To our knowledge, the present study is the first to use
a HF model to conduct experiments on a 3-day old biofilm of a
single S. aureus strain to assess the activity of drugs combination,
over 5 days, on both planktonic bacteria and BEB. The HF model
had already been used to simulate in two distinct studies the
free concentration-time profiles of amikacin or vancomycin that
can be achieved in patients receiving the recommended doses
(Nicasio et al., 2012; Ferro et al., 2015). In our study, exposure
to different dosage regimens of a susceptible strain of S. aureus
with MICs of 1 µg/mL for amikacin and vancomycin led to
equal or higher values of the PK/PD indices than those classically
expected to obtain drug efficacy (Zelenitsky et al., 2003; Rybak
et al., 2009; Song et al., 2015). For aminoglycosides, for which
the most predictive PK/PD index is the Cmax/MIC ratio (Moore
et al., 1987), we targeted Cmax/MIC values from 70 to 130 in the
HF model whereas a value from 8 to 10 is usually recommended
to ensure efficacy against the pathogen (Toutain et al., 2002).
For vancomycin, for which the best predictive index is the AUC
over 24 h divided by the MIC (AUC24 h/MIC) (Nielsen et al.,
2011), we targeted the value of 400 recommended to achieve
clinical effectiveness (Rybak et al., 2009; Jung et al., 2014; Song
et al., 2015) and obtained AUC24 h/MIC values ranging from
372 to 417 for the bolus of vancomycin in the HFIM and 480
for the constant infusion. Even though these targeted values
of the PK/PD indices were attained for both drugs, almost
no bactericidal activity was observed on the 3-day old biofilm
or on the co-existing planktonic bacteria when amikacin or
vancomycin were administered alone for 5 days. These results are
in agreement with previous studies which demonstrated the low
activity of vancomycin on large bacterial inocula (LaPlante and
Rybak, 2004; LaPlante and Woodmansee, 2009) and on biofilms
(Hogan et al., 2016). One study involving a HF model showed
that a peak concentration as high as 80 mg/L was needed to
achieve bactericidal activity against a large inoculum of a MRSA
strain with a MIC of 1 µg/mL for vancomycin (Lenhard et al.,
2016). One proposed explanation for the inoculum effect and
reduced efficacy of vancomycin is that bacteria at high density
are in a stationary growth phase with low dividing rate and low
cell wall synthesis (Brown et al., 1988; Lamp et al., 1992). Another
explanation is that vancomycin may be sequestrated by S. aureus
on peptidoglycan layers, thus reducing the free vancomycin
concentrations surrounding the bacteria (Srinivasan et al., 2002;
Ekdahl et al., 2005; Yanagisawa et al., 2009). Finally, a reduced
penetration of vancomycin through S. aureus and S. epidermidis
biofilms has also been described (Doroshenko et al., 2014; Singh
et al., 2016) and, even worse than the lack of efficacy, low
concentrations of vancomycin were reported to stimulate biofilm
formation in some clinical isolates of S. epidermidis (Cargill
and Upton, 2009). In this study on S. aureus, our results were
concordant as the biofilm which was exposed to vancomycin
alone contained 10 times more bacteria than the control.
The lack of efficacy of the drugs used in monotherapy in
this study supports the clinical recommendation to associate
an aminoglycoside with vancomycin for the treatment of
S. aureus biofilm infection (Deresinski, 2009). Compared with the
absence of activity of amikacin or vancomycin alone, exposure
to combinations of vancomycin and amikacin for 5 days in
the HF model had a synergistic bactericidal effect on the
planktonic bacterial populations. However, despite this synergy,
the planktonic bacteria remaining after 5 days of exposure to the
combination (D7) still exceeded 2.5 log10 CFU/mL. We therefore
investigated the ability of other dosage regimens of amikacin
and vancomycin to improve the antibacterial efficacy against this
planktonic population. Contrary to our expectations, given the
concentration-dependent activity of aminoglycosides, increasing
the Cmax of amikacin 1.8-fold (from 70 to 130 µg/mL) did not
increase the efficacy on planktonic bacteria. For vancomycin,
the efficacy of the combination seemed to be slightly decreased
by constant rate infusion, especially on planktonic bacteria,
but there were not enough replicates to draw a definitive
conclusion. Contrary to the planktonic population, the addition
of vancomycin (as a bolus or constant infusion) to amikacin
did not result in an additional bacterial reduction on S. aureus
biofilm, and no synergy between the two drugs was observed.
The distinct activity of the combination on planktonic bacteria
and BEB confirmed the different phenotypes of these two
populations of bacteria and that the drugs were less active on
BEB. Indeed, biofilms are supposed to contain more persister
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bacteria which have lower growth rates and are therefore less
affected by antibiotic drugs (Singh et al., 2009; Conlon et al.,
2015). Moreover, no dosing regimen tested in this study, even
if it exceeded the recommended PK/PD index values, was able
to fully eradicate the planktonic bacteria co-existing with a
biofilm, which could suggest that some planktonic bacteria were
continuously released from the biofilm. As our study is the first
one focusing on the biofilm in the HF, microscopy imaging will
be further needed to investigate the distribution of the biofilm
in the HF cartridge, which could be influenced, among others,
by the shear forces in the extracapillary space. It should also be
kept in mind that our system was characterized by an absence of
the immune system and the presence of a rich medium – more
favorable to bacterial growth -, that both limit the efficacy of
antibiotic treatments compared to the in vivo situation. However,
our in vitro results are in agreement with the reported lack of
efficacy of systemic antibiotic treatments in patients for whom
additional treatments, such as mechanical removal of biofilms or
very high local antibiotic concentrations, are advised whenever
possible (McConoughey et al., 2014; Wu et al., 2015).
In addition to efficacy, we assessed the ability of the
combination to reduce the selection of resistant bacteria in
planktonic and biofilm populations. The absence of resistance
to vancomycin in this study was in accordance with other
experiments conducted on S. aureus (LaPlante and Rybak, 2004).
Conversely, bacteria (approximately 10−6) able to grow on agar
supplemented with 6 µg/mL (sixfold MIC) of amikacin were
systematically present in the planktonic and biofilm populations
before drug exposure, implying that small proportions of such
bacteria are spontaneously present in large populations, as
previously reported (Ferro et al., 2015). Since similar proportions
were also found at the end of the control experiments, it suggests
that the growth and survival rates of less-susceptible and fully
susceptible bacteria were similar in the absence of drugs. After
5 days of antibiotic exposure, the MIC of amikacin for these
bacteria able to grow on agar supplemented with amikacin
and termed “less-susceptible,” never exceeded the resistance
breakpoint (>16 µg/mL). These bacteria showed an intermediate
amikacin-susceptibility with regard to the EUCAST breakpoints,
implying that the administration of amikacin to patients infected
by these bacteria would have an uncertain therapeutic effect
(Rodloff et al., 2008), but it should also be stressed that the
initial MIC of the tested strain was low (1 µg/mL). This suggests
that the same selection phenomenon occurring on a strain with
a two or four-fold higher MIC would lead to the selection of
“true” resistant bacteria. The selection of less-susceptible bacteria,
which represented the main population of planktonic bacteria
and BEB after exposure for 5 days to amikacin in monotherapy,
could be explained by an inducible mechanism of resistance,
known as adaptive resistance, in which thickening of the cell
wall results in less penetration of amikacin into the bacterial
cell (Yuan et al., 2013). Interestingly, the addition of vancomycin
to amikacin considerably reduced the proportions of these
less-susceptible bacteria in both planktonic bacteria and BEB
compared to amikacin alone, especially when vancomycin was
administered in boluses. These results suggest that vancomycin
was able to limit the growth of these bacteria less-susceptible
to amikacin and prevent their selection. The vancomycin
administered by CRI associated with amikacin seemed to limit
the selection of less-susceptible bacteria to a lesser extent, but
these differences require more thorough investigation.
CONCLUSION
By studying planktonic bacteria and BEB in parallel and by
mimicking the fluctuations in antibiotic concentrations over
5 days, as can occur in vivo after daily administrations, we
demonstrated the increased efficacy of a combination of amikacin
and vancomycin on planktonic bacteria but not on BEB.
However, even though vancomycin did not increase the killing
activity of amikacin on BEB, it reduced the selection of bacteria
less-susceptible to amikacin, which could help to maintain the
efficacy of this drug during treatments. Even if these results
need to be further confirmed with clinically relevant strains of
MSSA and MRSA, they highlight the importance of selecting
combination therapies not only based on efficacy but also on
resistance selection endpoints by taking into account the 2 co-
existing populations of planktonic bacteria and BEB.
Equations:
Concentration HF =
(Concentration CR ∗ Volume CR)+
(Concentration ECS ∗ Volume ECS)
Volume CR+ Volume ECS (1)
With HF being the Hollow-Fiber, CR the Central Reservoir
and ECS the Extra-Capillary Space.
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